4852-21-5 Usage
Description
1-Allyl-6-aminouracil is a chemical compound with the molecular formula C7H10N4O2. It is a derivative of uracil and is commonly used in the synthesis of pharmaceutical compounds. This chemical has properties that make it useful for various biological applications, particularly in the field of medicine.
Used in Pharmaceutical Industry:
1-Allyl-6-aminouracil is used as a precursor for the synthesis of nucleosides and nucleotides for the development of new drugs.
Used in Antiviral Applications:
1-Allyl-6-aminouracil is used as an antiviral agent for the treatment of viral infections due to its potential antiviral properties.
Used in Anticancer Applications:
1-Allyl-6-aminouracil is used as an anticancer agent for the treatment of cancer due to its potential anticancer properties.
Check Digit Verification of cas no
The CAS Registry Mumber 4852-21-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,8,5 and 2 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 4852-21:
(6*4)+(5*8)+(4*5)+(3*2)+(2*2)+(1*1)=95
95 % 10 = 5
So 4852-21-5 is a valid CAS Registry Number.
4852-21-5Relevant articles and documents
NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY
-
Paragraph 00306; 00311, (2016/06/20)
Compositions or an assembly of a series of biomimetic compounds include chemical structures that mimic or structurally resemble a nucleic acid base pair. Complexes of nanotubes and agents are useful to deliver agents into the cells or bodily tissues of individuals for therapeutic and diagnostic purposes. Exemplary compounds include those of Formula (I), (III), (V) or (VII), or of Formula (II), (IV), (VI) or (VIII).
Diazinane Compounds
-
Page/Page column 14, (2009/04/24)
The present invention relates to novel compounds of the general formula (I) wherein R1, R2, R3 and R4 are as defined, having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS).
